Cargando…

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

BACKGROUND: Neuroendocrine carcinomas of the prostate (NEPCs) are rare tumors with poor prognosis. While platinum and etoposide-based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, evidence for second-line therapy and beyond is very limited. METHODS: Retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apostolidis, Leonidas, Nientiedt, Cathleen, Winkler, Eva Caroline, Berger, Anne Katrin, Kratochwil, Clemens, Kaiser, Annette, Becker, Anne-Sophie, Jäger, Dirk, Hohenfellner, Markus, Hüttenbrink, Clemens, Pahernik, Sascha, Distler, Florian A., Grüllich, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343754/ https://www.ncbi.nlm.nih.gov/pubmed/30713600 http://dx.doi.org/10.18632/oncotarget.26523

Ejemplares similares

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
por: Zschäbitz, Stefanie, et al.
Publicado: (2017)

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease
por: Zschäbitz, Stefanie, et al.
Publicado: (2018)

Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma()
por: Zhou, Xiaoguang, et al.
Publicado: (2014)

Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma
por: Apostolidis, Leonidas, et al.
Publicado: (2016)

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2016)

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
por: Dietz, Steffen, et al.
Publicado: (2017)

Personalized Prediction of Patient Radiation Exposure for Therapy of Urolithiasis: An Application and Comparison of Six Machine Learning Algorithms
por: Huettenbrink, Clemens, et al.
Publicado: (2023)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

Genomic features of renal cell carcinoma with venous tumor thrombus
por: Warsow, Gregor, et al.
Publicado: (2018)

Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)
por: Apostolidis, Leonidas, et al.
Publicado: (2021)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial
por: Berger, Anne Katrin, et al.
Publicado: (2018)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Liver metastasis of a neuroendocrine tumor demonstrates intense uptake in PSMA-PET—but not its lymph-node metastasis and primary-tumor
por: Winter, Erik, et al.
Publicado: (2023)

Downstaging and Pathological Complete Response of Locally Recurrent Sarcomatoid Renal Cell Carcinoma under Pembrolizumab and Lenvatinib: A Case Report and Review of Literature
por: Ell, Jascha, et al.
Publicado: (2023)

Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms
por: Apostolidis, Leonidas, et al.
Publicado: (2021)

Patient expectations are better for immunotherapy than traditional chemotherapy for cancer
por: Ihrig, Andreas, et al.
Publicado: (2020)

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
por: Li, Jielin, et al.
Publicado: (2021)

Positive somatostatin receptor scintigraphy in accessory spleen mimicking recurrent neuroendocrine tumor
por: Takesh, Mustafa, et al.
Publicado: (2015)

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer()
por: Mang, Josef, et al.
Publicado: (2015)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Neural Networks Modeling for Prediction of Required Resources for Personalized Endourologic Treatment of Urolithiasis
por: Huettenbrink, Clemens, et al.
Publicado: (2022)

Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced Prostate Cancer
por: Schwarz, Sebastian, et al.
Publicado: (2023)

Paraganglioma of the Seminal Vesicle Case Report and Review of the Literature
por: Tosev, Georgi, et al.
Publicado: (2016)

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
por: Hoefflin, Rouven, et al.
Publicado: (2016)

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
por: Knoll, Maximilian, et al.
Publicado: (2015)

Prognostic relevance of androgen receptor expression in renal cell carcinomas
por: Foersch, Sebastian, et al.
Publicado: (2017)

Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis
por: Berger, Anne Katrin, et al.
Publicado: (2020)

Multicenter Analysis of Presacral Neuroendocrine Neoplasms—Clinicopathological Characterization and Treatment Outcomes of a Rare Disease
por: Matrood, Sami, et al.
Publicado: (2021)

Significance of the Intraoperative Methylene Blue Test for Postoperative Evaluation of the Vesicourethral Anastomosis
por: Nyarangi-Dix, J. N., et al.
Publicado: (2012)

Treatment Options for Pancreatic Neuroendocrine Tumors
por: Akirov, Amit, et al.
Publicado: (2019)

The biological relevance of gastric neuroendocrine tumors.
por: Klöppel, G., et al.
Publicado: (1996)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
por: Dermine, Solène, et al.
Publicado: (2019)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Primary melanoma of the prostate: case report and review of the literature
por: Tosev, Georgi, et al.
Publicado: (2015)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

The patient-level effect of the cost of Cancer care – financial burden in German Cancer patients
por: Mehlis, Katja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4nchklv1h2a4eo262nbk172ppt